These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 17062696

  • 1. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
    Wong TW, Lee FY, Yu C, Luo FR, Oppenheimer S, Zhang H, Smykla RA, Mastalerz H, Fink BE, Hunt JT, Gavai AV, Vite GD.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6186-93. PubMed ID: 17062696
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.
    Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E, Reich MF, Shen R, Shi X, Tsou HR, Wang YF, Wissner A.
    Cancer Res; 2004 Jun 01; 64(11):3958-65. PubMed ID: 15173008
    [Abstract] [Full Text] [Related]

  • 4. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.
    Bishop PC, Myers T, Robey R, Fry DW, Liu ET, Blagosklonny MV, Bates SE.
    Oncogene; 2002 Jan 03; 21(1):119-27. PubMed ID: 11791182
    [Abstract] [Full Text] [Related]

  • 5. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
    Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J.
    Clin Cancer Res; 1997 Nov 03; 3(11):2099-106. PubMed ID: 9815602
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.
    Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, Agus DB, Koeffler HP.
    Cancer; 2005 Dec 15; 104(12):2701-8. PubMed ID: 16265675
    [Abstract] [Full Text] [Related]

  • 8. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
    Nagasawa J, Mizokami A, Koshida K, Yoshida S, Naito K, Namiki M.
    Int J Urol; 2006 May 15; 13(5):587-92. PubMed ID: 16771730
    [Abstract] [Full Text] [Related]

  • 9. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Hickinson DM, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, Beck S, Marshall G, Davenport S, Callis R, Mills E, Grosios K, Smith P, Barlaam B, Wilkinson RW, Ogilvie D.
    Clin Cancer Res; 2010 Feb 15; 16(4):1159-69. PubMed ID: 20145185
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF, Zhu XF, Shang Y, Zhang SH, Zhen YS.
    Clin Cancer Res; 2010 Apr 01; 16(7):2085-94. PubMed ID: 20332319
    [Abstract] [Full Text] [Related]

  • 12. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
    Forsberg S, Ostman A, Rollman O.
    Arch Dermatol Res; 2008 Oct 01; 300(9):505-16. PubMed ID: 18446355
    [Abstract] [Full Text] [Related]

  • 13. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
    Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K.
    Cancer Res; 2001 Oct 01; 61(19):7196-203. PubMed ID: 11585755
    [Abstract] [Full Text] [Related]

  • 14. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
    Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, Mukherjee A, Sperinde J, Pannu H, Chenna A, DeFazio-Eli L, Pidaparthi S, Badal Y, Wallweber G, Chen L, Williams S, Tahir H, Larson J, Goodman L, Whitcomb J, Petropoulos C, Winslow J.
    Diagn Mol Pathol; 2009 Mar 01; 18(1):11-21. PubMed ID: 19214113
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Reid A, Vidal L, Shaw H, de Bono J.
    Eur J Cancer; 2007 Feb 01; 43(3):481-9. PubMed ID: 17208435
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL.
    Clin Cancer Res; 2008 Nov 15; 14(22):7272-83. PubMed ID: 19010843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.